Tumor-induced death of immune cells: Its mechanisms and consequences

Seminars in Cancer Biology

Volumn 12, Issue 1, 2002, Pages 43-50

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer; Fas; FasL interactions; Immune cells

Indexed keywords

CYTOKINE; FAS LIGAND; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL DEATH; CELL INFILTRATION; CLINICAL PATHWAY; CYTOKINE RELEASE; EFFECTOR CELL; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INFLAMMATION; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN FAMILY; TISSUE NECROSIS;

EID: 0036155925     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0402     Document Type: Article

References (63)

1. Specific inhibition of lymphocyte blastogenic responses to mitogens by a factor produced by cultured human malignant lymphoma cells
2. Lymphoid infiltration and prognosis in colorectal carcinoma
3. Tumor immunology: The glass is half full
4. The role of Fas/FasL in immunosuppression induced by human tumors
5. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
6. T cell immunity to tumor antigens
7. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients
8. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allograft
9. Antitumor effect of locally produced CD95 ligand
10. Fas ligand-induced apoptosis as a mechanism of immune privilege
11. The role of FasL-induced apoptosis in immune privilege
12. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
13. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
14. Human lung carcinomas express Fas ligand
15. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain
16. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
17. The Fas counterattack in vivo: Apoptotic depletion of tumor infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
18. Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
19. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian cancer cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes
20. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions
21. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes
22. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary, carcinomas
23. Fas ligand expression by thyroid carcinomas: A mechanism of immune evasion
24. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas
25. Human melanoma cells do not express Fas (APO-1/CD95) ligand
26. The tumor counterattack hypothesis revisited: Colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway
27. Metalloproteinase-mediated release of human Fas ligand
28. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase
29. Expression of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms
30. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma
31. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: Correlation with the prognostic factors
32. Prognostic relevance of altered Fas (CD95) system in human breast cancer
33. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis
34. FasL:Fas ratio - A prognostic factor in breast carcinomas
35. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival
36. Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion
37. Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing Fas ligand: A mechanism of immune evasion
38. Tumor-derived Fas ligand induces toxicity in lymphoid organs and plays an important role in successful chemotherapy
39. + peripheral blood T lymphocytes of patients with melanoma
40. A modified JAM assay detects apoptosis induced in activated lymphocytes by FasL+ human tumor cells
41. Tumor-induced apoptosis of T lymphocyte: Elucidation of intracellular apoptotic events
42. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition
43. Resistance of tumor cells to Fas-mediated apoptosis in head and neck cancer
44. Inhibition of Fas death signals by FLIPs
45. FAP-1: A protein tyrosine phosphatase that associates with Fas
46. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
47. Constitutive expression of FasL in thyrocytes
48. Human immune cells in the tumor microenvironment: Mechanisms responsible for signaling and functional defects
49. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer
50. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma
51. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
52. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival
53. Expression of the functional soluble form of human Fas ligand in activated lymphocytes
54. Programmed cell death as a mechanism of CD4 and CD8 T cell deletion in AIDS. Molecular control and effect of highly active anti-retroviral therapy
55. Gene transfer of Fas ligand induces tumor regression in vivo
56. Antitumor effect of locally produced CD95 ligand
57. Regulation of the proinflammatory effects of Fas ligand (CD95L)
58. Fas-mediated apoptosis in Ewings' sarcoma cell lines by metallo-proteinase inhibitors
59. The Fas counterattack: A molecular mechanism of tumor immune privilege
60. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells